Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 16, 2007

Ardea Receives $0.5M from Valeant upon Selection of Development Candidates

  • Ardea Biosciences received its first milestone payment of $0.5 million from Valeant Pharmaceuticals. The fee was triggered by Valeant's selection of several pre-IND candidates for its potassium-channel opener program.

    In December 2006, Ardea bought certain discovery and preclinical assets from Valeant. Separately, Valeant also signed a deal to pay Ardea for research on unidentified neurological treatments.

    "Starting with a very interesting first-generation compound, we have successfully improved its metabolic and pharmacokinetic properties, while increasing potency by up to 50-fold,” says Barry D. Quart,  president and CEO of Ardea. “We are pleased to be recognized for achieving this important milestone and for its validation of our fully-integrated discovery, research, and development platform.”

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »